Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

28-03-2018 | EMA | News

approvalsWatch

Rucaparib authorization recommended for relapsed, progressive ovarian cancer

print
PRINT
insite
SEARCH

medwireNews: The EMA has adopted a positive opinion for use of the PARP inhibitor rucaparib in patients with progressive or relapsed ovarian cancer.

The Committee for Medicinal Products for Human Use has recommended that rucaparib be given as a monotherapy against BRCA-mutated, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Specifically, the agent may be given to patients with platinum-sensitive, relapsed or progressive disease who have previously received two or more lines of platinum-based chemotherapy and are unable to tolerate further treatment.

By Lynda Williams

medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group

See also:

print
PRINT